Abstract
For generations, women have relied on fertility awareness methods (FAM) to plan and prevent pregnancy; for over a decade, many have been aided by digital tools to do so. New Contraceptive Fertility Tracking Apps (CFTAs)--that are backed by clinical efficacy trials to support their effectiveness as contraception--have the potential to enhance method choice and offer users a unique contraceptive option, but there is little evidence to inform the decisions around expanding access, particularly in low-and middle-income countries (LMICs). We conducted a mixed methods study with quantitative online surveys (n=1600) and qualitative components (n=36) to explore the potential appeal of and demand for a hypothetical CFTA in one such market, the Philippines. Interest in using a CFTA was high among our internet-engaged, urban study population, with 83.9% “definitely” or “probably” interested in using. Across demographic profiles, respondents perceived the appeal of the method as “natural” and “convenient.” A majority were willing to pay for the method, though notably at a price (5.20 USD) below that of currently available CFTAs. We explore various factors to be considered before bringing a method like this to new markets, including equity constraints and the prevalence of other period-tracking apps not intended as contraception.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This manuscript is made possible by the generous support of the American people through the United States Agency for International Development (USAID), cooperative agreement #No. AID-OAA-A-13-00088. The contents of this paper are the sole responsibility of the authors and do not necessarily reflect the views of USAID or the United States Government.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Research Ethics Board of Population Services International and the National Ethics Committee of the Philippines gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data for this manuscript will be available publicly in a de-identified format from the USAID Data Development Library (DDL).
https://nam11.safelinks.protection.outlook.com/?url=https%3A%2F%2Fdata.usaid.gov%2Fd%2F2s8u-n2vw&data=05%7C01%7Ckdanna%40psi.org%7C80176a14e0a7445f92b908db91eb290e%7Ccd9cb8ece621472a979a549ab5ba2470%7C0%7C0%7C638264211446003329%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C3000%7C%7C%7C&sdata=jzSRPb2QCaS0MpXz4qa9PgHbwY2wBLXUnuYR5PPOR2A%3D&reserved=0
